The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

9 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis.

Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology drug Dupixent as a therapy for rare skin disease prurigo nodularis (PN).

Gabriele Muekusch, RN, is a Staff Nurse, Phototherapy Education and Research Centre, Women's College Hospital, Toronto, Ontario, Canada. Judith Pitman, RN, is a Staff Nurse, Phototherapy Education ...

Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the ...

and phase 3 testing in prurigo nodularis is also due to start before the end of 2024. Sanofi is, however, lagging behind rival Novartis in the development of an oral BTK inhibitor for CSU ...

What if you could point something at your skin — in the comfort of your own home, no less — and decrease skin problems like wrinkles and acne? That’s the promise of light wands. Light ...

The BiliLux is a compact and lightweight LED phototherapy light system for the treatment of neonatal jaundice. It provides superior phototherapy performance, individualized therapy with electronic ...